Use of a PAK inhibitor for the treatment of a joint disease

Details for Australian Patent Application No. 2004260590 (hide)

Owner Sanofi-Aventis Deutschland GmbH

Inventors Klatt, Andreas R.; Bartnik, Eckart; Czech, Joerg; Leberer, Ekkehard; Leeuw, Thomas; Barradeau, Sebastian

Agent Watermark

Pub. Number AU-B-2004260590

PCT Pub. Number WO2005/011721

Priority 03016303.4 18.07.03 EP

Filing date 15 July 2004

Wipo publication date 10 February 2005

Acceptance publication date 3 June 2010

International Classifications

A61K 38/08 (2006.01) Medicinal preparations containing peptides - Peptides having 5 to 11 amino acids

A61K 38/45 (2006.01) Medicinal preparations containing peptides

A61P 19/02 (2006.01) Drugs for skeletal disorders

C07K 16/40 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against enzymes

Event Publications

9 February 2006 PCT application entered the National Phase

  PCT publication WO2005/011721 Priority application(s): WO2005/011721

3 June 2010 Application Accepted

  Published as AU-B-2004260590

30 September 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004260591-Vapor-permeable and waterproof sole for shoes, particularly but not exclusively for open shoes such as sandals, sabots and the like, and shoe provided with the sole

2004260588-Liquid formulation